Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
New to Comunitee?

or Sign Up with Email



APR 04, 2014 - Yahoo! News

A Must Read - Share

Halozyme halts trial of drug delivery system, shares slump

Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling 32 percent. The biotechnology company said it halted enrollment and patient dosing as a "precautionary measure" following the recommendation of an independent safety committee. The pancreatic cancer study was testing a more potent form of the company's existing technology to deliver chemotherapy drugs intravenously and to prolong the effectiveness of its synthetic enzyme, Hylenex, in the blood stream. Halozyme ... Read More

Tags: Halozyme halts trial of drug delivery system, shares slump,  Pancreatic Cancer Latest News